
From: Masha Drokova <[REDACTED]>
Sent: Friday, November 3, 2017 7:19 AM
To: jeffrey E.
Subject: Re:

what is investor type btw? what is one main quality for investor?

On Nov 2, 2017, at 9:53 PM, jeffrey E. <jeevacation@gmail.com <mailto:jeevacation@gmail.com>> wrote:

He is not an investor type . He is a partner at a firm but used to be at Microsoft. Just use him for advice<=div>

On Thu, Nov 2, 2017 at 11:13 PM Masha Drokova [REDACTED]
> wrote:

=div>
Thank you for the comprehensive feedback Steven.
=div>

<=div>For me the main value is that the system is an order of magnitude cheaper than existing technologies, premised on leveraging data to help users see what daily elements are affecting their blood sugar, and predicting dangerous highs and lows before they happen so they can take actions beforehand. To date, their beta app has lowered blood sugar averages in over 55% of users 2x better than the world's most prescribed diabetes drug, Metformin. Which means that with the help of the device diabetes would need to use less drugs. However I'd agree on complexity of regulations and saturation on the market.

I run Day=One Ventures fund and based in San Francisco. I'd be happy to connect in person sometime to learn about your experience and tell about our investments and opportunities I see.

On Nov 2, 2017, at 3:24 PM, Steven Sinofsky [REDACTED] >>
wrote:

=blockquote type="cite">
Greetings Masha,

I apologize for the delay. I was at some events in the UK where I did not have connectivity.

I have worked on a related portfolio company so I will have to be a bit abstract on the specifics of this opportunity. So please excuse these brief thoughts. Also, the only information I had was what was provided in your mail which was limited relative to any detailed analysis.

* In general the challenge with glucose measurement is the finger prick. Any device that relies on this will only be marginally better than any other device, whether or not there is software or a slightly more convenient

measuring device. This is a statement about the inconvenience of a prick (and long term challenges but also the medical challenges on relying on that point in time.

* My sense is that going down the path of an innovation, that still has a prick, but requires a level of FDA approval is a difficult one to approach.</=iv>

* This is a very crowded space. There are a lot of apps, a lot of measuring devices, a lot of mixtures of app and measuring devices. It is very difficult to avoid appearing as a commodity to consumers.

* While I understand there is potential to see innovation using novel approaches to analysis of data, it is not clear to me how much better the approach can be for an individual with data.

* The real opportunity I might see is around measuring glucose or some related telemetry to assist in compliance that is outside the scope of a finger prick and measuring glucose directly. It seems like we should have some other data point upon which to apply machine learning.

I hope this helps...any friend of JE is a friend of mine.

On Nov 1, 2017, at 4:43 PM, Masha Drokova &= [REDACTED]

[REDACTED] > wrote:

</=iv>

Thank you Jeffrey. Steve, great meeting you.

Would appreciate your feedback

On Nov 1, 2017, at 9:31 AM, jeff=ey E. <jeevac=tion@gmail.com
<mailto:jeevacation@gmail.com> > wrote:

<=iv>steve can you give some guidance

On Wed, Nov 1, 2017 at 12:20 PM, Masha Drokova <=pan> <[REDACTED]

[REDACTED] > wrote:

I'm looking to invest at the company doing AI-based glucose monitoring system for people with diabetes. We made tech evaluation, talked to a few experts and more a question about the market and regulations. Likely no, because it's complex area, but still thinking of them.

May be someone in=your network who knows this area and can advise on this kind of tech? =/span>

=font face="Roboto-Regular">Center Health

Deck:

Pros

— Existing glucometers from big companies are very old-fashioned and outdated, those companies make their revenue from overpriced

— Direct competitors, such as iHealth and Dario have negative customer reviews and minor

— Uses FDA-approved circuits to get the approval in an automated manner

Cons

- Enormous pressure both from the industry players and companies such as Apple and Google that try to develop non-invasive glucose monitoring that will wipe out test strip products
- Hardware startup without a product to sell yet, finalizing the development
- Young team

--

please note

confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE

Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com

<<mailto:jeevacation@gmail.com>> , and

destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved

=/div>

=/div>

--

&nb=p; please note

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE

Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com <<mailto:jeevacation@gmail.com>> , and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved

=